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In the cation of the title salt, C8H13N4
+C4H3O4, the
piperazinium ring adopts a slightly distorteded chair confor-
mation. In the crystal, a single strong O—H  O inter-
molecular hydrogen bond links the anions, forming chains
along the c-axis direction. The chains of anions are linked by
the cations, via N—H  O hydrogen bonds, forming sheets
parallel to (100). These layers are linked by weak C—H  O
hydrogen bonds, forming a three-dimensional structure. In
addition, there are weak – interactions [centroid–centroid
distance = 3.820 (9) A˚] present involving inversion-related
pyrimidine rings.
Related literature
For heterocyclic compounds that exhibit a broad spectrum of
biological activities see: Amin et al. (2009); Clark et al. (2007);
Ibrahim & El-Metwally (2010); Kim et al. (2010); Kuyper et al.
(1996); Padmaja et al. (2009); Pandey et al. (2004). For piper-
azine-based compounds of biological and chemotherapeutic
importance, see: Abdel-Jalil et al. (2010). For piperazine
derivatives that have reached the stage of clinical application
among the known drugs to treat anxiety, see: Tollefson et al.
(1991). For related structures, see: Betz et al. (2011); Fun et al.
(2012); Jasinski et al. (2010, 2011); Kavitha et al. (2013);
Ravikumar & Sridhar (2005); Siddegowda et al. (2011). For
puckering parameters, see Cremer & Pople (1975). For stan-







a = 12.3425 (5) A˚
b = 7.0365 (3) A˚
c = 14.7178 (6) A˚
 = 94.213 (3)
V = 1274.77 (9) A˚3
Z = 4
Cu K radiation
 = 0.94 mm1
T = 173 K
0.22  0.16  0.06 mm
Data collection
Agilent Xcalibur Eos Gemini
diffractometer
Absorption correction: multi-scan
(CrysAlis PRO and CrysAlis
RED; Agilent, 2012).
Tmin = 0.840, Tmax = 1.000
8262 measured reflections
2455 independent reflections
2090 reflections with I > 2(I)
Rint = 0.039
Refinement
R[F 2 > 2(F 2)] = 0.040




H atoms treated by a mixture of
independent and constrained
refinement
max = 0.23 e A˚
3
min = 0.27 e A˚3
Table 1
Hydrogen-bond geometry (A˚, ).
D—H  A D—H H  A D  A D—H  A
N1A—H1AA  O2Bi 0.99 1.79 2.7601 (15) 166
N1A—H1AB  O4Bii 0.99 1.78 2.7493 (16) 167
C8A—H8A  O2Biii 0.95 2.53 3.3133 (18) 140
O1B—H1B  O3Biv 1.12 (3) 1.35 (3) 2.4679 (13) 176 (3)
Symmetry codes: (i) x;yþ 32; z 12; (ii) xþ 1; y 12;zþ 12; (iii)x þ 2;yþ 1;zþ 1; (iv) x;yþ 32; zþ 12.
Data collection: CrysAlis PRO (Agilent, 2012); cell refinement:
CrysAlis PRO; data reduction: CrysAlis RED (Agilent, 2012);
program(s) used to solve structure: SUPERFLIP (Palatinus &
Chapuis, 2007); program(s) used to refine structure: SHELXL2012
(Sheldrick, 2008); molecular graphics: OLEX2 (Dolomanov et al.,
2009); software used to prepare material for publication: OLEX2.
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4-(Pyrimidin-2-yl)piperazin-1-ium (E)-3-carboxyprop-2-enoate
Thammarse S. Yamuna, Manpreet Kaur, Jerry P. Jasinski and H. S. Yathirajan
S1. Comment 
Pyrimidine derivatives have attracted organic chemists due to their biological and chemotherapeutic importance. Related 
fused heterocycles are important classes of heterocyclic compounds that exhibit a broad spectrum of biological activities 
such as anticancer (Amin et al., 2009; Pandey et al., 2004), antiviral (Ibrahim & El-Metwally, 2010), antibacterial 
(Kuyper et al., 1996), antioxidant (Padmaja et al. , 2009), antidepressant (Kim et al., 2010) and anti-inflammatory (Clark 
et al., 2007). Piperazine-based compounds have been employed as antibacterial, antidepressant, and antitumor drugs, and 
as α adrenoceptor antagonists, CCR5 receptor antagonists, 5-HT7 receptor antagonists, and adenosine A2a receptor 
antagonists (Abdel-Jalil et al., 2010). Several piperazine derivatives have reached the stage of clinical application among 
the known drugs that are used to treat anxiety including the pyrimidinyl piperazinyl compounds, buspirone and BuSpar 
(Tollefson et al., 1991). The incorporation of two moieties increases biological activity of both the molecules. Our 
research group has published many papers on incorporated heterocyclic ring structures, viz; imatinibium dipicrate 
[systematic name: 1-methyl-4-(4-{4-methyl-3- [4-(3-pyridyl)pyrimidin-2-ylamino]anilinocarbonyl}benzyl)-
piperazine-1,4- diium dipicrate, (Jasinski et al., 2010), 1-(2-hydroxyethyl)-4-{3-[(E)-2-(trifluoromethyl)-9H-
thioxanthen-9- ylidene]propyl}piperazine-1,4-diium bis(3-carboxyprop-2-enoate) (Siddegowda et al., 2011), 
lomefloxacinium picrate (Jasinski et al., 2011), paliperidone: 3-{2-[4-(6-fluoro-1,2-benzoxazol-3- yl)piperidin-1-
yl]ethyl}-9-hydroxy-2-methyl-1,6,7,8,9,9a-hexahydropyrido [1,2-a]pyrimidin-4-one (Betz et al., 2011), 4-[3,5-bis(2-hy-
droxy phenyl)-1H-1,2,4-triazol-1-yl]benzoic acid dimethylformamide monosolvate (Fun et al., 2012), and other related 
crystal structures are quetiapine hemifumarate (systematic name: 1-[2-(2-hydroxyethoxy) ethyl]- 4-(dibenzo[b,f][1,4]thia-
zepin-11-yl)piperazinium hemifumarate (Ravikumar & Sridhar, 2005), Cinnarizinium fumarate (Kavitha et al., 2013). In 
view of the importance of the incorporated of heterocyclic ring compounds and derivative of pyrimidyl piperazines, this 
paper reports the crystal structure of the title salt.
The title salt crystallizes with one independent monoprotonated piperazinium cation (A) and one independent fumarate 
anion (B) in the asymmetric unit (Fig. 1). In the cation, the piperazinium ring adopts a slightly distorted chair 
conformation (puckering parameters Q, θ, and φ = 0.5738 (14) Å, 5.20 (14)° and 21.1 (16)° (Cremer & Pople, 1975). 
Bond lengths are in normal ranges (Allen et al., 1987).
In the crystal, a single strong short O1B—H1B···O3B hydrogen bond links the anions resulting in chains along the c 
axis (Table 1 and Fig. 2). The chains are linked via N—H···O hydrogen bonds to form sheets parallel to (100). A weak 
C8A—H8A···O2B hydrogen bond links the cations and anions forming a three-dimensional structure with alternate layers 
of cations and anions (Table 1 and Fig. 2). In addition, weak π–π interactions involving inversion related pyrimidine rings 
are present [Cg–Cgi = 3.820 (9) Å; symmetry code:(i) -x+2, -y+1, -z+1; Cg is the centroid of the pyrimidine ring 
N3A/N4A/C5A-C8A].
supporting information
sup-2Acta Cryst. (2014). E70, o702–o703    
S2. Experimental 
1-(2-Pyrimidyl)piperazine (Sigma-Aldrich; 0.2 g, 1.2179 mmol) and fumaric acid (0.1412 g, 1.2179 mmol ) were 
dissolved in 10 ml of dimethylsulfoxide and stirred at 333 K for 20 minutes. After a few days, colourless block-like 
crystals were obtained on slow evaporation of the solvent [M.p: 433-438 K].
S3. Refinement 
Atom H1B was freely refined and all of the remaining H atoms were placed in their calculated positions and refined using 
the riding model approach: N-H = 0.99 Å for NH2 H atoms, C—H = 0.95 and 0.99Å for CH and CH2 H atoms, 
respectively, with Uiso(H) = 1.2Ueq(N,C).
Figure 1
A view of the molecular structure of the title salt, with atom labelling. Displacement ellipsoids are drawn at the 30% 
probability level. 
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Figure 2
A view along the b axis of the crystal packing of the title salt. Hydrogen bonds are shown as dashed lines (see Table 1 for 






a = 12.3425 (5) Å
b = 7.0365 (3) Å
c = 14.7178 (6) Å
β = 94.213 (3)°
V = 1274.77 (9) Å3
Z = 4
F(000) = 592
Dx = 1.460 Mg m−3
Cu Kα radiation, λ = 1.54184 Å
Cell parameters from 3297 reflections
θ = 3.6–71.5°
µ = 0.94 mm−1
T = 173 K
Block, colourless
0.22 × 0.16 × 0.06 mm
Data collection 
Agilent Xcalibur Eos Gemini 
diffractometer
Radiation source: Enhance (Cu) X-ray Source
Detector resolution: 16.0416 pixels mm-1
ω scans
Absorption correction: multi-scan 
(CrysAlis PRO and CrysAlis RED; Agilent, 
2012).
Tmin = 0.840, Tmax = 1.000
8262 measured reflections
2455 independent reflections
2090 reflections with I > 2σ(I)
Rint = 0.039















Primary atom site location: structure-invariant 
direct methods
Hydrogen site location: mixed
H atoms treated by a mixture of independent 
and constrained refinement
w = 1/[σ2(Fo2) + (0.0626P)2 + 0.2118P] 
where P = (Fo2 + 2Fc2)/3
(Δ/σ)max < 0.001
Δρmax = 0.23 e Å−3
Δρmin = −0.27 e Å−3
Extinction correction: SHELXL2012 (Sheldrick, 
2008), Fc*=kFc[1+0.001xFc2λ3/sin(2θ)]-1/4
Extinction coefficient: 0.0012 (3)
Special details 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance 
matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; 
correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate 
(isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
x y z Uiso*/Ueq
N1A 0.73318 (9) 0.69373 (17) 0.20819 (8) 0.0218 (3)
H1AA 0.6882 0.7451 0.1554 0.026*
H1AB 0.6968 0.5788 0.2299 0.026*
N2A 0.91562 (9) 0.69808 (17) 0.33676 (8) 0.0212 (3)
N3A 0.98791 (10) 0.77052 (18) 0.48251 (9) 0.0244 (3)
N4A 1.09665 (9) 0.62261 (18) 0.37363 (9) 0.0248 (3)
C1A 0.74267 (11) 0.8382 (2) 0.28219 (10) 0.0223 (3)
H1AC 0.6694 0.8739 0.2997 0.027*
H1AD 0.7785 0.9539 0.2605 0.027*
C2A 0.80895 (11) 0.7569 (2) 0.36402 (10) 0.0214 (3)
H2AA 0.8179 0.8540 0.4127 0.026*
H2AB 0.7707 0.6463 0.3882 0.026*
C3A 0.91155 (11) 0.5639 (2) 0.26058 (9) 0.0230 (3)
H3AA 0.8806 0.4418 0.2798 0.028*
H3AB 0.9861 0.5395 0.2429 0.028*
C4A 0.84275 (11) 0.6420 (2) 0.17953 (10) 0.0232 (3)
H4AA 0.8782 0.7557 0.1554 0.028*
H4AB 0.8355 0.5453 0.1306 0.028*
C5A 1.00316 (11) 0.69522 (19) 0.40052 (10) 0.0186 (3)
C6A 1.07633 (13) 0.7795 (2) 0.54032 (11) 0.0281 (4)
H6A 1.0695 0.8347 0.5985 0.034*
C7A 1.17713 (12) 0.7133 (2) 0.52036 (12) 0.0287 (4)
H7A 1.2390 0.7224 0.5625 0.034*
C8A 1.18203 (12) 0.6329 (2) 0.43523 (12) 0.0285 (4)
H8A 1.2495 0.5823 0.4194 0.034*
O1B 0.45437 (8) 0.79460 (16) 0.54884 (7) 0.0247 (3)
O2B 0.62685 (8) 0.69817 (16) 0.54483 (7) 0.0274 (3)
O3B 0.48860 (8) 0.68609 (15) 0.21591 (6) 0.0227 (3)
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O4B 0.33707 (8) 0.85812 (15) 0.22066 (6) 0.0228 (3)
C1B 0.53605 (11) 0.73177 (19) 0.50805 (9) 0.0170 (3)
C2B 0.51599 (11) 0.70263 (19) 0.40767 (9) 0.0173 (3)
H2B 0.5605 0.6157 0.3779 0.021*
C3B 0.43843 (11) 0.79386 (19) 0.35918 (9) 0.0174 (3)
H3B 0.3918 0.8740 0.3906 0.021*
C4B 0.41910 (10) 0.77939 (19) 0.25776 (9) 0.0159 (3)
H1B 0.473 (2) 0.801 (4) 0.624 (2) 0.091 (10)*
Atomic displacement parameters (Å2) 
U11 U22 U33 U12 U13 U23
N1A 0.0163 (6) 0.0294 (7) 0.0188 (6) −0.0046 (5) −0.0057 (5) 0.0051 (5)
N2A 0.0132 (6) 0.0313 (7) 0.0186 (6) 0.0027 (4) −0.0023 (4) −0.0025 (5)
N3A 0.0187 (6) 0.0321 (7) 0.0216 (7) 0.0000 (5) −0.0037 (5) −0.0027 (5)
N4A 0.0156 (6) 0.0291 (7) 0.0294 (7) 0.0033 (5) −0.0019 (5) −0.0006 (5)
C1A 0.0141 (6) 0.0272 (7) 0.0249 (7) 0.0001 (5) −0.0025 (5) 0.0018 (6)
C2A 0.0128 (6) 0.0314 (7) 0.0194 (7) 0.0014 (5) −0.0014 (5) −0.0016 (6)
C3A 0.0208 (7) 0.0297 (8) 0.0180 (7) 0.0028 (5) −0.0019 (5) −0.0023 (6)
C4A 0.0214 (7) 0.0312 (8) 0.0165 (7) −0.0020 (6) −0.0009 (5) 0.0003 (6)
C5A 0.0145 (6) 0.0202 (7) 0.0204 (7) −0.0013 (5) −0.0031 (5) 0.0030 (5)
C6A 0.0260 (8) 0.0332 (8) 0.0236 (8) −0.0031 (6) −0.0082 (6) −0.0005 (6)
C7A 0.0209 (7) 0.0297 (8) 0.0333 (9) −0.0019 (6) −0.0125 (6) 0.0050 (6)
C8A 0.0149 (7) 0.0286 (8) 0.0409 (9) 0.0023 (5) −0.0054 (6) 0.0016 (7)
O1B 0.0196 (5) 0.0454 (7) 0.0092 (5) 0.0021 (4) 0.0008 (4) −0.0006 (4)
O2B 0.0216 (5) 0.0433 (7) 0.0163 (5) 0.0075 (4) −0.0064 (4) −0.0044 (4)
O3B 0.0221 (5) 0.0362 (6) 0.0094 (5) 0.0091 (4) −0.0006 (4) −0.0012 (4)
O4B 0.0183 (5) 0.0329 (6) 0.0164 (5) 0.0056 (4) −0.0043 (4) −0.0029 (4)
C1B 0.0173 (6) 0.0209 (7) 0.0126 (7) −0.0017 (5) −0.0007 (5) 0.0011 (5)
C2B 0.0166 (6) 0.0241 (7) 0.0111 (6) −0.0008 (5) 0.0009 (5) −0.0004 (5)
C3B 0.0170 (6) 0.0244 (7) 0.0109 (6) 0.0008 (5) 0.0020 (5) −0.0020 (5)
C4B 0.0153 (6) 0.0206 (7) 0.0115 (6) −0.0012 (5) −0.0001 (5) 0.0001 (5)
Geometric parameters (Å, º) 
N1A—H1AA 0.9900 C3A—C4A 1.5157 (19)
N1A—H1AB 0.9900 C4A—H4AA 0.9900
N1A—C1A 1.4883 (19) C4A—H4AB 0.9900
N1A—C4A 1.4909 (18) C6A—H6A 0.9500
N2A—C2A 1.4640 (17) C6A—C7A 1.380 (2)
N2A—C3A 1.4637 (18) C7A—H7A 0.9500
N2A—C5A 1.3782 (17) C7A—C8A 1.380 (2)
N3A—C5A 1.3438 (19) C8A—H8A 0.9500
N3A—C6A 1.3351 (19) O1B—C1B 1.2890 (17)
N4A—C5A 1.3477 (18) O1B—H1B 1.12 (3)
N4A—C8A 1.3407 (19) O2B—C1B 1.2311 (17)
C1A—H1AC 0.9900 O3B—C4B 1.2742 (16)
C1A—H1AD 0.9900 O4B—C4B 1.2445 (16)
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C1A—C2A 1.5173 (19) C1B—C2B 1.4941 (17)
C2A—H2AA 0.9900 C2B—H2B 0.9500
C2A—H2AB 0.9900 C2B—C3B 1.3181 (19)
C3A—H3AA 0.9900 C3B—H3B 0.9500
C3A—H3AB 0.9900 C3B—C4B 1.4977 (17)
H1AA—N1A—H1AB 108.1 N1A—C4A—H4AA 109.8
C1A—N1A—H1AA 109.6 N1A—C4A—H4AB 109.8
C1A—N1A—H1AB 109.6 C3A—C4A—H4AA 109.8
C1A—N1A—C4A 110.45 (10) C3A—C4A—H4AB 109.8
C4A—N1A—H1AA 109.6 H4AA—C4A—H4AB 108.2
C4A—N1A—H1AB 109.6 N3A—C5A—N2A 116.82 (12)
C3A—N2A—C2A 114.29 (11) N3A—C5A—N4A 126.34 (13)
C5A—N2A—C2A 119.56 (12) N4A—C5A—N2A 116.80 (13)
C5A—N2A—C3A 119.55 (11) N3A—C6A—H6A 118.1
C6A—N3A—C5A 115.41 (13) N3A—C6A—C7A 123.76 (15)
C8A—N4A—C5A 115.36 (13) C7A—C6A—H6A 118.1
N1A—C1A—H1AC 109.8 C6A—C7A—H7A 122.2
N1A—C1A—H1AD 109.8 C8A—C7A—C6A 115.59 (14)
N1A—C1A—C2A 109.39 (11) C8A—C7A—H7A 122.2
H1AC—C1A—H1AD 108.2 N4A—C8A—C7A 123.47 (14)
C2A—C1A—H1AC 109.8 N4A—C8A—H8A 118.3
C2A—C1A—H1AD 109.8 C7A—C8A—H8A 118.3
N2A—C2A—C1A 109.41 (12) C1B—O1B—H1B 111.6 (15)
N2A—C2A—H2AA 109.8 O1B—C1B—C2B 115.42 (12)
N2A—C2A—H2AB 109.8 O2B—C1B—O1B 125.37 (12)
C1A—C2A—H2AA 109.8 O2B—C1B—C2B 119.20 (12)
C1A—C2A—H2AB 109.8 C1B—C2B—H2B 119.0
H2AA—C2A—H2AB 108.2 C3B—C2B—C1B 121.98 (13)
N2A—C3A—H3AA 109.5 C3B—C2B—H2B 119.0
N2A—C3A—H3AB 109.5 C2B—C3B—H3B 117.9
N2A—C3A—C4A 110.78 (12) C2B—C3B—C4B 124.24 (12)
H3AA—C3A—H3AB 108.1 C4B—C3B—H3B 117.9
C4A—C3A—H3AA 109.5 O3B—C4B—C3B 116.94 (11)
C4A—C3A—H3AB 109.5 O4B—C4B—O3B 124.90 (12)
N1A—C4A—C3A 109.46 (11) O4B—C4B—C3B 118.15 (12)
N1A—C1A—C2A—N2A 57.34 (15) C5A—N3A—C6A—C7A −1.5 (2)
N2A—C3A—C4A—N1A −54.53 (16) C5A—N4A—C8A—C7A −0.6 (2)
N3A—C6A—C7A—C8A −0.6 (2) C6A—N3A—C5A—N2A −174.86 (13)
C1A—N1A—C4A—C3A 59.07 (15) C6A—N3A—C5A—N4A 2.9 (2)
C2A—N2A—C3A—C4A 54.41 (16) C6A—C7A—C8A—N4A 1.8 (2)
C2A—N2A—C5A—N3A −8.22 (19) C8A—N4A—C5A—N2A 175.90 (13)
C2A—N2A—C5A—N4A 173.80 (12) C8A—N4A—C5A—N3A −1.9 (2)
C3A—N2A—C2A—C1A −55.43 (16) O1B—C1B—C2B—C3B 23.25 (19)
C3A—N2A—C5A—N3A −158.13 (13) O2B—C1B—C2B—C3B −155.66 (14)
C3A—N2A—C5A—N4A 23.89 (19) C1B—C2B—C3B—C4B 176.05 (12)
C4A—N1A—C1A—C2A −60.83 (14) C2B—C3B—C4B—O3B −6.6 (2)
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C5A—N2A—C2A—C1A 153.15 (13) C2B—C3B—C4B—O4B 173.29 (13)
C5A—N2A—C3A—C4A −154.17 (13)
Hydrogen-bond geometry (Å, º) 
D—H···A D—H H···A D···A D—H···A
N1A—H1AA···O2Bi 0.99 1.79 2.7601 (15) 166
N1A—H1AB···O4Bii 0.99 1.78 2.7493 (16) 167
C8A—H8A···O2Biii 0.95 2.53 3.3133 (18) 140
O1B—H1B···O3Biv 1.12 (3) 1.35 (3) 2.4679 (13) 176 (3)
Symmetry codes: (i) x, −y+3/2, z−1/2; (ii) −x+1, y−1/2, −z+1/2; (iii) −x+2, −y+1, −z+1; (iv) x, −y+3/2, z+1/2.
